Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDS Aridis Pharmaceuticals	$0.00 -50.0%	$0.00	$0.00 ▼ $0.01	$5K	12.15	11,881 shs	21,814 shs
NAVB Navidea Biopharmaceuticals	$0.00	$0.00	$0.00 ▼ $0.13	$50K	1.71	7,603 shs	35 shs
SMFL Smart for Life	$0.00 -69.4%	$0.01	$0.00 ▼ $1.56	$23K	17.05	6,340 shs	1,949 shs
VRPX Virpax Pharmaceuticals	$0.01 +11.8%	$0.19	$0.01 ▼ $26.25	$15K	1.49	169,058 shs	1,734 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDS Aridis Pharmaceuticals	0.00%	0.00%	0.00%	-50.00%	-99.00%
NAVB Navidea Biopharmaceuticals	0.00%	0.00%	0.00%	-28.57%	-50.00%
SMFL Smart for Life	-69.44%	-46.77%	-91.75%	+32.00%	-99.79%
VRPX Virpax Pharmaceuticals	+11.82%	+11.82%	-38.50%	-94.65%	-99.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDS Aridis Pharmaceuticals	0.00	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	0.00	N/A	N/A	N/A
SMFL Smart for Life	0.00	N/A	N/A	N/A
VRPX Virpax Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	$8.13K	6.16	N/A	N/A	N/A	∞
SMFL Smart for Life	$11.11M	0.00	N/A	N/A	($17.10) per share	0.00
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	$1.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDS Aridis Pharmaceuticals	-$30.37M	N/A	∞	N/A	N/A	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	-$15.18M	N/A	∞	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	-$22.68M	N/A	∞	N/A	N/A	N/A	N/A	N/A
VRPX Virpax Pharmaceuticals	-$15.19M	N/A	∞	N/A	N/A	-1,554.34%	-338.29%	N/A

Latest ARDS, SMFL, NAVB, and VRPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/11/2025	Q3 2024	SMFL Smart for Life	N/A	-$0.94	N/A	-$0.94	N/A	$1.27 million
5/23/2025	Q2 2024	SMFL Smart for Life	N/A	-$2.41	N/A	-$2.34	N/A	$0.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A	N/A	N/A
VRPX Virpax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A
SMFL Smart for Life	N/A	N/A	N/A
VRPX Virpax Pharmaceuticals	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDS Aridis Pharmaceuticals	9.65%
NAVB Navidea Biopharmaceuticals	0.01%
SMFL Smart for Life	28.39%
VRPX Virpax Pharmaceuticals	32.23%

Insider Ownership

Company	Insider Ownership
ARDS Aridis Pharmaceuticals	5.50%
NAVB Navidea Biopharmaceuticals	43.68%
SMFL Smart for Life	31.71%
VRPX Virpax Pharmaceuticals	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDS Aridis Pharmaceuticals	30	53.32 million	50.39 million	Not Optionable
NAVB Navidea Biopharmaceuticals	10	100.08 million	56.37 million	Optionable
SMFL Smart for Life	110	7.09 million	4.84 million	Not Optionable
VRPX Virpax Pharmaceuticals	7	1.24 million	4.71 million	Not Optionable

ARDS, SMFL, NAVB, and VRPX Headlines

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news

April 3, 2025 | investing.com

Virpax Pharmaceuticals Inc trading halted, news pending

March 21, 2025 | markets.businessinsider.com

Virpax reports positive results in Probudur dog study

March 20, 2025 | investing.com

Virpax receives positive Probudur results for dose range study

March 20, 2025 | markets.businessinsider.com

Virpax Pharmaceuticals announces 1-for-25 reverse stock split

March 20, 2025 | markets.businessinsider.com

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

March 18, 2025 | finance.yahoo.com

Virpax Pharmaceuticals files to sell common stock and warrants, no amount given

March 18, 2025 | markets.businessinsider.com

Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET

March 11, 2025 | msn.com

Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference

March 11, 2025 | msn.com

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

March 7, 2025 | businesswire.com

Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)

March 6, 2025 | markets.businessinsider.com

Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS

March 5, 2025 | finance.yahoo.com

Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology

March 3, 2025 | msn.com

Virpax lauds Nanomerics’ MET study with no severe side effects

March 1, 2025 | investing.com

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

February 27, 2025 | finance.yahoo.com

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

February 27, 2025 | businesswire.com

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

February 13, 2025 | joplinglobe.comJ

Virpax Pharmaceuticals confirms results with U.S. Army with Probudur

February 13, 2025 | markets.businessinsider.com

Virpax reports positive study results for pain management drug

February 13, 2025 | msn.com

Virpax Pharmaceuticals appoints new independent director

February 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS, SMFL, NAVB, and VRPX Company Descriptions

Aridis Pharmaceuticals NASDAQ:ARDS

$0.0001 0.00 (-50.00%)

As of 08/22/2025 01:40 PM Eastern

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Navidea Biopharmaceuticals NYSE:NAVB

$0.0005 0.00 (0.00%)

As of 08/22/2025

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Smart for Life NASDAQ:SMFL

$0.0033 -0.01 (-69.44%)

As of 08/22/2025 02:52 PM Eastern

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.

Virpax Pharmaceuticals NASDAQ:VRPX

$0.01 +0.00 (+11.82%)

As of 08/22/2025 03:45 PM Eastern

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time